Life sciences company Revvity (NYSE:RVTY) announced in Q1 CY2025, with sales up 2.3% year on year to $664.8 million. The company’s full-year revenue guidance of $2.85 billion at the midpoint came in 0 ...

WALTHAM, Mass. & SAN DIEGO--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced a strategic agreement to commercialize an in vitro diagnostic (IVD) workflow solution for neonatal sequencing, ...

Add Yahoo as a preferred source to see more of our stories on Google. Waltham-based biomanufacturing company Revvity is closing its Boston facility and laying off dozens of employees as a result.

Revvity Inc. (NYSE:RVTY) stock is trading lower on Monday following the life science tools maker’s second-quarter 2025 earnings report, which also included a trimmed profit forecast for 2025. The ...

Earlier this week, Revvity reported stronger-than-expected Q4 2025 results, with Diagnostics delivering 10% reported revenue growth and management issuing upbeat full-year 2026 guidance calling for ...

Revvity (NYSE:RVTY) will release its quarterly earnings report on Monday, 2025-04-28. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Revvity to report an earnings ...